Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib

International Journal of Hematology

Volumn 93, Issue 6, 2011, Pages 727-735

  Nakano, Ayako ^a   Abe, Masahiro ^a   Oda, Asuka ^a   Amou, Hiroe ^a   Hiasa, Masahiro ^b   Nakamura, Shingen ^a   Miki, Hirokazu ^a   Harada, Takeshi ^a   Fujii, Shirou ^a   Kagawa, Kumiko ^a   Takeuchi, Kyoko ^a   Watanabe, Takashi ^c   Ozaki, Shuji ^d   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bortezomib induced peripheral neuropathy; Myeloma; N Acetyl l cysteine; Vitamin C

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; BORTEZOMIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CELL INCLUSION; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; MYELOMA CELL; NEUROPROTECTION; NONHUMAN; RAT; SCHWANN CELL; THERAPY DELAY;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; AUTOPHAGY; BORONIC ACIDS; CELL LINE; ENDOPLASMIC RETICULUM; FREE RADICAL SCAVENGERS; MULTIPLE MYELOMA; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RATS; SCHWANN CELLS;

EID: 79960091205     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0850-7     Document Type: Article

References (25)

1. PG Richardson P Sonneveld MW Schuster EA Stadtmauer T Facon JL Harousseau 2009 Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Br J Haematol 144 895 903
2. AA Argyriou G Iconomou HP Kalofonos 2008 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood 112 1593 1599
3. A Badros O Goloubeva JS Dalal I Can J Thompson AP Rapoport 2007 Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature Cancer 110 1042 1049 (Pubitemid 47312870)
4. PG Richardson H Briemberg S Jagannath PY Wen B Barlogie J Berenson 2006 Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol 24 3113 3120 (Pubitemid 46638949)
5. G Cavaletti A Gilardini A Canta L Rigamonti V Rodriguez-Menendez C Ceresa 2007 Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat Exp Neurol 204 317 325 (Pubitemid 46330280)
6. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311-19.
7. Pazdro R, Burgess JR. The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev. 2010;131:276-86.
8. AK Naik SK Tandan SP Dudhgaonkar SH Jadhav M Kataria VR Prakash 2006 Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats Eur J Pain 10 573 579 (Pubitemid 44278713)
9. T Pan S Kondo W Zhu W Xie J Jankovic W Le 2008 Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement Neurobiol Dis 32 16 25
10. A Hennigan RM O'Callaghan AM Kelly 2007 Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection Biochem Soc Trans 35 424 427 (Pubitemid 46596521)
11. JD Evans TF Jacobs EW Evans 2008 Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy Ann Pharmacother 42 1686 1691
12. RP Agrawal J Goswami S Jain DK Kochar 2009 Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study Diabetes Res Clin Pract 83 371 378
13. C He DJ Klionsky 2009 Regulation mechanisms and signaling pathways of autophagy Annu Rev Genet 43 67 93
14. EA Obeng LM Carlson DM Gutman WJ Harrington Jr KP Lee LH Boise 2006 Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 4907 4916 (Pubitemid 43882644)
15. SJ Padayatty H Sun Y Wang HD Riordan SM Hewitt A Katz 2004 Vitamin C pharmacokinetics: implications for oral and intravenous use Ann Intern Med 140 533 537
16. I Medved MJ Brown AR Bjorksten JA Leppik S Sostaric MJ McKenna 2003 N-Acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans J Appl Physiol 94 1572 1582 (Pubitemid 36348838)
17. W Zou P Yue N Lin M He Z Zhou S Lonial 2006 Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells Clin Cancer Res 12 273 280 (Pubitemid 43166204)
18. G Perrone T Hideshima H Ikeda Y Okawa E Calabrese G Gorgun 2009 Ascorbic acid inhibits antitumor activity of bortezomib in vivo Leukemia 23 1679 1686
19. NB Nedelsky PK Todd JP Taylor 2008 Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection Biochim Biophys Acta 1782 691 699
20. Watanabe T, Nagase K, Chosa M, Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer. 2010;103:1580-7.
21. L Papa P Rockwell 2008 Persistent mitochondrial dysfunction and oxidative stress hinder neuronal cell recovery from reversible proteasome inhibition Apoptosis 13 588 599
22. ZX Du HY Zhang X Meng Y Guan HQ Wang 2009 Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells BMC Cancer 9 56
23. JM May Z Qu X Li 2001 Requirement for GSH in recycling of ascorbic acid in endothelial cells Biochem Pharmacol 62 873 881 (Pubitemid 32816973)
24. SP Treon BA Chabner 1996 Concepts in use of high-dose methotrexate therapy Clin Chem 42 1322 1329 (Pubitemid 26265051)
25. E Warnick D Auger 2009 Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate Clin J Oncol Nurs 13 177 180